+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Capacity and tolerance of a new device for ocular drug delivery

Capacity and tolerance of a new device for ocular drug delivery

International Journal of Pharmaceutics 341(1-2): 152-161

A new method to increase the drug-capacity of the OphthaCoil, a flexible and tubular device for delivery of drugs to the tear film of the eye, was explored. Poly(2-hydroxyethyl methacrylate)- and poly (2-hydroxyethyl methaerylate-co-1-vinyl-2-pyrrolidone)-microspheres were prepared by suspension polymerization. The resultant particles were swollen in a highly concentrated solution of either the dye fluorescein sodium or the antibiotic chloramphenicol. The loaded particles were placed in the central cavity of the ocular device. In vitro release profiles showed a six-fold increase of the capacity for the dye fluorescein sodium, but not for the antibiotic chloramphenicol. Flexibility measurements revealed that by introducing microspheres in the central cavity of the device, flexibility did not decrease. Finally, a preliminary in vivo evaluation of the device (n = 5) was done for a 2 h-period to assess the tolerance of the device in the human eye. Ophthalmologic examinations and photographs of the eye indicated no signs of irritation. Volunteers reported that the presence of the device in the eye could be noticed, but no irritation was reported.

(PDF emailed within 0-6 h: $19.90)

Accession: 015207371

Download citation: RISBibTeXText

PMID: 17524579

DOI: 10.1016/j.ijpharm.2007.04.007

Related references

In vivo tolerance and kinetics of a novel ocular drug delivery device. Journal of Controlled Release 116(2): E47-E49, 2007

Ocular drug delivery device. Official Gazette of the United States Patent & Trademark Office Patents 1224(4), Jul 27, 1999

Design of an implantable device for ocular drug delivery. Journal of Drug Delivery 2012: 527516-527516, 2012

A flexible device for ocular iontophoretic drug delivery. Biomicrofluidics 10(1): 011911-011911, 2016

Design and in vitro biocompatibility of a novel ocular drug delivery device. Journal of Functional Biomaterials 4(1): 14-26, 2013

Release of antibiotic to the ocular surface by a ciprofloxacin-containing drug delivery device. IOVS 42(4): S172, March 15, 2001

A refillable microfabricated drug delivery device for treatment of ocular diseases. Lab on A Chip 8(7): 1027-1030, 2008

Massive clonidine overdose during refill of an implanted drug delivery device for intrathecal analgesia: a review of inadvertent soft-tissue injection during implantable drug delivery device refills and its management. Pain Medicine 12(7): 1032-1040, 2011

Contact lenses as a drug delivery device for epidermal growth factor in the treatment of ocular wounds. Clinical & Experimental Optometry 93(2): 61-65, 2010

Current ocular drug delivery challenges for N-acetylcarnosine: novel patented routes and modes of delivery, design for enhancement of therapeutic activity and drug delivery relationships. Recent Patents on Drug Delivery & Formulation 3(3): 229-265, 2010

Drug delivery device having improved adhesion and attachment system for drug delivery device. Official Gazette of the United States Patent & Trademark Office Patents 1272(1), July 1, 2003

Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Investigative Ophthalmology & Visual Science 47(4): 1416-1425, 2006

Electrically controlled drug-delivery system may help minimize side effects: remotely controlled drug-delivery device may be a step towards ‘smart’ closed-loop drug-eluting systems. Nanomedicine 9(5): 569-570, 2015

Drug delivery device for programmed delivery of beneficial drug us patent 4624847 nov 25 1986. Official Gazette Of The United States Patent & Trademark Office Patents4: 1639, 1986

Ocular permeability of FITC-dextran with absorption promoter for ocular delivery of peptide drug. Journal of Drug Targeting 3(2): 129-135, 1995